2083 results about "Extracellular vesicles" patented technology

The invention relates to method and kits for highly specific isolation of extracellular vesicles (EVs) by targeting at least two EV surface markers. The invention further relates to methods and kits for analyzing EVs and their contents.

The invention discloses a blood extracellular vesicle miRNA (micro Ribonucleic Acid), miRNAs (micro Ribonucleic Acid) hsa-miR-150-3p, hsa-miR-150-5p, hsa-miR-335-3p, hsa-miR-375, hsa-miR-4433b-5p and hsa-miR-4732-5p, which can be used as biomarkers for early diagnosis of lung cancer, so that the blood extracellular vesicle miRNA can be used for preparing a chip, a detection reagent or a detection kit for early diagnosis of lung cancer. The blood extracellular vesicle miRNA biomarker disclosed by the invention has high sensitivity and high specificity on early diagnosis of lung cancer, so that false positive caused by a traditional diagnosis method can be reduced, and the miRNA biomarker has a potential good clinical application value.

The invention discloses a method for extracting extracellular vesicles from dried Sanguisorba officinalis rhizomes and application of the extracellular vesicles, and relates to the technical field of molecular biology and biomedicine.The method comprises the following steps that S1, rehydration is conducted, specifically, the dried Sanguisorba officinalis rhizomes are subjected to liquid nitrogen quick freezing and then ground into powder at the low temperature, the powder and hydration liquid are mixed according to the proportion of 1: 10 (w / v), the mixture is slowly stirred for 2-4 h at the temperature of 4 DEG C, and the extracellular vesicles are obtained; removing large-particle impurities by using sterile gauze or a filter screen, and collecting filtrate; according to the method, through the synergistic effect of multiple enzymolysis and in combination with cellulase, pectinase and the like, the degradation efficiency is remarkably improved, meanwhile, EDTA is chelated with metal ions, and the enzymolysis effect is enhanced. Short-time alternating ultraviolet light is introduced to activate'dormant 'vesicles, so that the yield and the biological activity are improved. Secondly, multiple protection mechanisms, such as vitamin C, EDTA (Ethylene Diamine Tetraacetic Acid), cane sugar, BSA (Bovine Serum Albumin) and an ultraviolet protective agent are adopted, so that the integrity and the biological activity of the vesicles are ensured.

The invention relates to compositions (e.g., pharmaceutical compositions), uses, methods, non-therapeutic and therapeutic methods related to senolytic agents encapsulated or comprised in Muse cell derived extracellular vesicles (e.g. exosomes). Such compositions and methods are useful for specifically killing senescent cells and reverting any symptoms, disorders or diseases associated with senescence.

The disclosure provides technologies that permit detection and / or characterization of brain biomarkers (e.g., disease-associated biomarkers) in non-CNS samples, including by liquid biopsy (e.g., blood, serum, etc.). Among other things, the present disclosure demonstrates that ultrasound opening of the blood brain barrier can achieve detectable increases in brain-derived materials (e.g., brain-derived proteins, neuron-derived extracellular vesicles, and / or cell-free DNA) in readily-sampled systemic liquids.

The invention discloses a preparation method and application of a universal renewable immunoaffinity magnetic bead, and belongs to the technical field of chemical detection.The preparation method comprises the steps that firstly, an engineered bacteriophage H6G5-M13 is constructed, then a polypeptide module is coupled to the engineered bacteriophage H6G5-M13, the polypeptide module comprises a part A, a part B and a part C from the N end to the C end, the part A is a target object recognition sequence located at the N end, and the part C is a target object recognition sequence located at the C end; the part B is a selectively added connecting sequence, the part C is an LPXTG substrate sequence and is located at the C end, and X refers to any amino acid; finally, the engineered bacteriophage is directionally coupled to the Ni < 2 + >-IDA magnetic bead through the action of Ni-6His, and then the universal and novel immunoaffinity magnetic bead is formed. The universal and replaceable immunoaffinity magnetic bead prepared by the method can be used for preparing a chemical detection reagent, and can also be used for capturing, releasing and sensing detection of cells and extracellular vesicles.

The invention relates to a drug delivery carrier based on extracellular vesicles and application thereof.The drug delivery carrier contains extracellular vesicle scaffold protein and recombinant membrane fusion protein, the recombinant membrane fusion protein comprises a first fragment and a second fragment, the amino acid sequence of the first fragment is shown as SEQ ID NO: 5, and the amino acid sequence of the second fragment is shown as SEQ ID NO: 6; the second fragment has n amino acids, the sequence of the second fragment is the sequence of the first n amino acids at the N end of the amino acid sequence as shown in SEQ ID NO: 7, and n is an integer between 50 and 200. According to the drug delivery carrier disclosed by the invention, the efficiency of releasing drug active molecules before reaching lysosome is remarkably improved, and the drug effect of extracellular vesicle drugs can be improved.

Long COVID or Post Acute Sequelae of COVID-19 (PASC), is a prolonged, debilitating syndrome that follows acute SARS-CoV-2 infection in >10% of cases. Human bone marrow mesenchymal stem cell derived extracellular vesicles (hBM-MSC EVs) can present a new therapeutic option.

The invention provides a traditional Chinese medicine meridian prescription system based on multi-omics integration analysis of extracellular vesicles, and the system comprises a data collection module which is used for collecting biopsy sample information of different groups of individuals based on related experiments and literatures of traditional Chinese medicine meridian prescription treatment; the data processing module is used for obtaining and preprocessing extracellular vesicle data and intestinal flora data based on biopsy sample information; the multi-omics integration module is used for obtaining multi-omics integration data; the discovery and verification module is used for obtaining the potential menstrual prescription drug effect evaluation biomarker and performing experimental verification on the potential menstrual prescription drug effect evaluation biomarker to obtain a verification result; and the system biology application module is used for obtaining a regulatory mechanism of the extracellular vesicles in a biological system based on construction of a gene-protein-metabolite interaction network. The invention can comprehensively reveal the pharmacodynamic mechanism of the traditional Chinese medicine menstrual prescription, and provides strong technical support and application prospect for the modern, scientific and internationalized development of traditional Chinese medicines.

The embodiment of the invention discloses a method for extracting extracellular vesicles from a traditional Chinese medicine dry product. The method comprises the following steps: taking a dry traditional Chinese medicine product as a raw material, and sequentially performing crushing, soaking, first-order enzymolysis, wall breaking, differential centrifugation, second-order enzymolysis, high-speed centrifugation, ultracentrifugation and ultrafiltration enrichment to obtain the extracellular vesicles. A two-step enzymolysis method is adopted in the enzymolysis process, impurities are removed to the maximum extent in a sequence difference enzymolysis mode, and the structure and function stability of the exosome are protected. According to the invention, the differential centrifugation and the enzymolysis method are alternately used, so that impurities with different sizes and different properties can be removed more thoroughly. According to the method, the cost is strictly controlled, the exosome purification efficiency is relatively high, the concentration of the obtained dry exosome is relatively high, and the operability is extremely high.

Disclosed are methods of treating radiation-induced skin damage comprising administering extracellular vesicle and protein compositions.

Disclosed are methods of treating traumatic brain injury in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Methods of treating lumbar facet joint syndrome by administering extracellular vesicle and protein compositions.

Disclosed are methods of treating patients receiving an organ transplant by administering extracellular vesicle composition.

The invention belongs to the technical field of biological medicines, and particularly relates to a sperm injury repair model and an establishment method thereof. Comprising the following steps: step 1, establishing a sperm lead poisoning model; and 2, establishing a lead poisoning sperm repair model. The method for establishing the lead poisoning sperm repair model in the step 2 comprises the following steps: (1) preparing a preparation for optimizing sperm functions in an extracellular vesicle way; (2) repairing the damaged sperms by using the preparation for optimizing the sperm function through the extracellular vesicles; and (3) detecting the activity of the repaired sperms. In the invention, by establishing a sperm injury repair model and adopting an extracellular vesicle modification technology, the key functional protein is introduced into the extracellular vesicle, and the method has important significance on auxiliary researches such as development and research of related drugs for improving sperm injury and improving sperm motility of asthenospermia patients in vitro.

Disclosed are methods of treating infertility or increasing fertility of a female subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention belongs to the field of biological medicines, and discloses an application of Akkermansia muciniphila or an extracellular vesicle of the Akkermansia muciniphila in preparation of a medicine for alleviating the ischemic necrosis of the alcoholic femoral head. Based on the pathogenesis characteristics of the AIONFH, the Akk bacteria and the extracellular vesicles thereof are used for treating the AIONFH for the first time, the molecular mechanism of the Akk bacteria and the extracellular vesicles thereof for regulating and controlling the intestinal tract-skeleton axis function, inhibiting bone cell apoptosis and improving the bone trabecula microstructure is deeply researched, the anti-pressure ability of bone tissue is improved, and the research blank in the field is filled. Compared with a traditional treatment method, the osteonecrosis pathological change is improved through a single way, and a novel multi-target treatment strategy is provided from multiple aspects of regulating inflammatory response, recovering bone metabolism balance, promoting intraosseous blood supply and the like.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention provides a method for separating extracellular vesicles from a milk source, which comprises the step of adding a dispersing agent before adding a precipitator into the milk source to precipitate casein so as to reduce the wrapping of protein precipitation on the extracellular vesicles and improve the yield of the extracellular vesicles, thereby obtaining a milk source extract rich in the extracellular vesicles.

The invention discloses a typing analysis method for extracellular vesicles secreted by tumor cells and immune cells, which comprises the following steps: designing a PD-L1 protein recognition aptamer PD-L1-L, an EpCAM protein recognition aptamer EpCAM-L and a molecular beacon according to different expression levels of surface markers of the extracellular vesicles (PD-L1 + and EpCAM +) derived from the tumor cells and the extracellular vesicles (PD-L1 + and EpCAM-) derived from the immune cells; when the DNA probe recognizes the extracellular vesicles, fluorescence of the Cy5-PD-L1-L aptamer of the tumor cell source extracellular vesicles is quenched, a fluorescence signal of the Connector is recovered, and the immune cell source extracellular vesicles do not respond, so that the two extracellular vesicles are subjected to typing analysis. The method has the advantages that the extracellular vesicles of different cell sources can be subjected to typing analysis by using a strategy based on double aptamers and double switches, and false positive signals caused by single aptamer recognition are avoided.

The invention belongs to the technical field of stem cell culture and exosome extraction, and provides an RELM beta pre-activated stem cell outer vesicle with high anti-inflammatory and anti-fibrosis activity. According to the method, the mesenchymal stem cells are subjected to hunger culture after being adhered to the wall and then are continuously cultured by a complete culture medium containing RELM beta factors, then supernate is collected, and the exovesicles are obtained through separation. In the preparation process of the extracellular vesicles, the paracrine function of MSC cells is promoted by the RELM beta, the secretion of anti-inflammatory and anti-fibrosis active factors is obviously activated, and the generation of the extracellular vesicles with enhanced anti-inflammatory and anti-fibrosis effects is promoted. Gene modification is not involved, toxic biochemical reagents or materials are not added, exogenous operation steps are simple and convenient, clinical application is guaranteed through sterile operation, no RELM beta residues exist after extracellular vesicle extraction, and the method is safe, non-toxic and effective.

The invention discloses a hydrogel-acellular matrix composite patch containing functionalized extracellular vesicles and a preparation method of the hydrogel-acellular matrix composite patch. The composite patch comprises a hydrogel layer and an acellular pericardium matrix material layer, and an extracellular vesicle-macrophage membrane fusion body (EV-MM) is entrapped in the cross-linked hydrogel. From two aspects of improving the targeting of EVs to the cardiac infarction part and enhancing the retention of the EVs at the cardiac infarction part, the distribution condition of the EVs at the cardiac infarction part is improved, so that the action efficiency of the EVs is improved, and the treatment effect is improved.

A novel Akkermansia muciniphila EB-AMDK39 strain (KCTC 13765BP) and composition containing the novel strain or extracellular vesicles (EVs) derived from the strain are disclosed. The composition can be in a form of pharmaceutical, food, or veterinary composition. The compositions are useful to preventing or treating cancer or inflammatory disease, or ameliorating cancer or inflammatory disease.

The invention discloses a bone joint repairing composition containing stem cell vesicles and application of the bone joint repairing composition, and relates to the technical field of bone joint repairing compositions.The bone joint repairing composition is prepared from, by weight, 90-110 parts of stem cell vesicles and 41-57 parts of thelenota ananas saponin Ananaside A. The stem cell vesicles and the thelenota ananas saponin Ananaside A are combined to form the bone joint repairing composition. The stem cell vesicles are extracellular vesicles derived from human amniotic mesenchymal stem cells. According to the bone joint repairing composition provided by the invention, the stem cell vesicles and the thelenota ananas saponin in a proper proportion are matched for use, so that the synergistic interaction between the stem cell vesicles and the thelenota ananas saponin is realized. Animal experiments show that the composition has a remarkable repairing effect on a rat model with bone and joint injuries, can effectively relieve bone and joint pain symptoms of rats, not only widens the application field of human amniotic mesenchymal stem cell-derived extracellular vesicles, but also provides a new clinical treatment means for bone and joint repairing.

The invention discloses a preparation method of artemisia apiacea extracellular vesicles, which comprises the following steps: step 1, pre-treating artemisia apiacea, carrying out primary centrifugal treatment, removing large plant tissues and cell debris, carrying out secondary centrifugal treatment, filtering by a needle filter, and collecting; step 2, transferring the filtered suspension to a sucrose density gradient solution, then carrying out third centrifugal treatment, collecting the solution with the concentration of 30% in the layer, and carrying out fourth centrifugal treatment to obtain artemisia apiacea extracellular vesicles; the invention further discloses an artemisia apiacea extracellular vesicle, a pharmaceutical composition for treating cerebral apoplexy, a medicine and application of the artemisia apiacea extracellular vesicle in preparation of the medicine for treating cerebral apoplexy. The naturally-sourced vesicle delivery system provided by the invention is expected to have higher safety and lower toxic and side effects, and the enrichment concentration of the therapeutic component at the focus part of cerebral apoplexy is improved, so that the bioavailability and the treatment efficiency of the medicine are remarkably improved.

The present invention provides a method for producing extracellular vesicles, the method including a step for passing a crushed liquid of plants, mushrooms, or microalgae through a depth filter, and a step for subjecting the crushed liquid after passing through the depth filter to ultrafiltration treatment, the depth filter being composed of filaments.

The invention discloses a biomarker for auxiliary diagnosis of progressive suprakaryotic paralysis and application thereof, and relates to the technical field of biomedicine. The biomarker is a neuron-derived extracellular vesicle carrying a Tau deformable protein; the Tau deformation protein is 4R Tau or pTau181, and the Tau deformation protein is a protein with the molecular weight of 4R The invention develops a biomarker capable of assisting in diagnosing progressive suprakaryotic paralysis, and the biomarker can be used for effectively identifying a progressive suprakaryotic paralysis (PSP) patient, a Parkinson's disease (PD) patient and a healthy person (HC). Meanwhile, a progressive supranuclear paralysis diagnosis model is also constructed, the sensitivity of the multivariable logistic regression model for distinguishing PSP and HC is 95.7%, the specificity is 90.0%, and the AUC is 0.974; the sensitivity of the multivariable logistic regression model for distinguishing PSP and PD is 96.3%, the specificity is 90.0%, and the AUC is 0.968.

The invention relates to an extracellular vesicle surface protein detection paper-based kit and application thereof, and belongs to the technical field of biology. The technical problems that an existing sEVs detection technology is insufficient in specificity, depends on professional instruments and cannot meet the instant detection requirement are solved. According to the method, sEVs are synergistically captured through double aptamers, the target specificity is improved, signals are amplified in a cascaded mode through hyper-branched rolling circle amplification (HRCA) and a CRISPR / Cas12a system, and visual detection is achieved by detecting FAM-biotin probe separation before and after cutting through a transverse flow test strip. According to the method, interference of free protein is effectively avoided through double-target recognition, and the detection limit is as low as 406 parts / mL; cRISPR and a paper-based technology are combined to realize high sensitivity and instant detection; the system is simple and convenient to operate, does not need professional instruments, is suitable for tumor diagnosis and treatment monitoring of clinical samples, and provides a portable solution for precise medical treatment.

The invention provides a method for detecting an external vesicle marker through high-flux nano plasma exciting light immune color development, and belongs to the technical field of human extracellular vesicles. After a serum sample is subjected to centrifugal treatment, the serum sample and a CD81 capture antibody substrate are incubated, and the particle size distribution of the vesicles is monitored in real time; a zwitterionic polymer modified gold nanoparticle LAM detection probe and a polyethylene glycol modified silver nanoparticle LprG detection probe are prepared to be specifically combined with a vesicle surface antigen, a chromogenic enhancement solution is adopted to induce a plasma resonance signal, and full-hole scanning imaging is carried out; and constructing a double-layer game optimization model to cooperatively optimize the detection sensitivity and the signal stability, carrying out weighted summation on normalized signals of the particle size subgroups to obtain comprehensive detection signal intensity, comparing the comprehensive detection signal intensity with a threshold value, and outputting a final judgment result. The technical problem that quantitative accuracy is affected by signal intensity deviation caused by vesicle particle size difference in outer vesicle marker detection is solved.

The invention relates to the technical field of biological medicines, in particular to rapamycin-induced extracellular vesicles and application thereof in preparation of a medicine for promoting wound repair. The rapamycin-induced extracellular vesicles can enhance the migration and tube forming ability of endothelial cells, so that angiogenesis is promoted; meanwhile, the proliferation and migration capabilities of macrophages can be inhibited, and the proportion of M1 type macrophages in a wound is reduced, so that the inflammatory response mediated by the macrophages is relieved; and the composition shows extraordinary effects in the aspect of accelerating wound repair. The biological activity of the extracellular vesicles induced by the rapamycin depends on the activation of a PI3K / Akt signal channel.